Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005

Int J Tuberc Lung Dis. 2012 Aug;16(8):1069-74. doi: 10.5588/ijtld.11.0696. Epub 2012 Jun 11.

Abstract

Setting: Multidrug-resistant tuberculosis (MDR-TB) treatment facility, Orel Oblast, Russian Federation.

Objectives: To determine factors associated with poor outcome and to document status of patients after recording of TB outcomes.

Design: Retrospective review of prospective single cohort.

Results: Among 192 patients, factors significantly associated with poor outcome in multivariate analysis include three or more treatment interruptions during the intensive phase of therapy and alcohol or drug addiction (adjusted OR [aOR] 2.1, 95%CI 1.0-4.3 and aOR 1.9, 95%CI 1.0-3.7). Previous treatment was associated with poor outcome, but only among smear-positive patients (aOR 3.1, 95%CI 1.3-7.3). Ten patients (5%) developed extensively drug-resistant TB (XDR-TB) during treatment; of 115 patients with at least 6 months of follow-up data after outcomes were recorded, 13 (11%) developed XDR-TB.

Conclusion: Interventions focused on supporting patient adherence during the intensive phase of treatment; the management of drug and alcohol addiction should be developed and studied. A substantial proportion of patients developed XDR-TB during and after treatment. Longer term follow-up data of patients treated for MDR-TB are needed to better inform programmatic policy.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Alcoholism / epidemiology
  • Antitubercular Agents / therapeutic use*
  • Chi-Square Distribution
  • Directly Observed Therapy
  • Female
  • Humans
  • Logistic Models
  • Male
  • Medication Adherence
  • Middle Aged
  • Multivariate Analysis
  • Mycobacterium tuberculosis / isolation & purification
  • Odds Ratio
  • Predictive Value of Tests
  • Recurrence
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Russia / epidemiology
  • Sputum / microbiology
  • Substance-Related Disorders / epidemiology
  • Time Factors
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / epidemiology
  • Tuberculosis, Multidrug-Resistant / microbiology
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / epidemiology
  • Tuberculosis, Pulmonary / microbiology
  • Young Adult

Substances

  • Antitubercular Agents